Click for best price
Multiparametric Invitro Cardiotoxicity Testing Market Size, Share 2024
The global Multiparametric In-vitro Cardiotoxicity Testing market was valued at US$ million in 2023 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2023, While China is to reach $ Million.
Calcium Transient Assay Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Multiparametric In-vitro Cardiotoxicity Testing include Creative Bioarray, Agilent Technologies, Inc., Hemogenix Inc., Merck KGaA, Molecular Devices, LLC., Miltenyi Biotec, FUJIFILM Cellular Dynamics, Enzo Life Sciences, Inc. and Axol Bioscience Ltd., etc. in 2023, the global top five players have a share approximately % in terms of revenue.
This report aims to provide a comprehensive presentation of the global market for Multiparametric In-vitro Cardiotoxicity Testing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Multiparametric In-vitro Cardiotoxicity Testing. This report contains market size and forecasts of Multiparametric In-vitro Cardiotoxicity Testing in global, including the following market information:
Global Multiparametric In-vitro Cardiotoxicity Testing Market Revenue, 2020-2024, 2025-2030, ($ millions)
Global top five companies in 2023 (%)
We surveyed the Multiparametric In-vitro Cardiotoxicity Testing companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Multiparametric In-vitro Cardiotoxicity Testing Market, by Type of Assay, 2020-2024, 2025-2030 ($ millions)
Global Multiparametric In-vitro Cardiotoxicity Testing Market Segment Percentages, by Type of Assay, 2023 (%)
Calcium Transient Assay
Cardiac Marker Detection
hERG Assay
Multi-ion Channel Assay
Others
Global Multiparametric In-vitro Cardiotoxicity Testing Market, by Application, 2020-2024, 2025-2030 ($ millions)
Global Multiparametric In-vitro Cardiotoxicity Testing Market Segment Percentages, by Application, 2023 (%)
Contract Research Organizations (CROs)
Pharmaceutical and Biotech Companies
Others
Global Multiparametric In-vitro Cardiotoxicity Testing Market, By Region and Country, 2020-2024, 2025-2030 ($ Millions)
Global Multiparametric In-vitro Cardiotoxicity Testing Market Segment Percentages, By Region and Country, 2023 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Multiparametric In-vitro Cardiotoxicity Testing revenues in global market, 2020-2024 (estimated), ($ millions)
Key companies Multiparametric In-vitro Cardiotoxicity Testing revenues share in global market, 2023 (%)
Further, the report presents profiles of competitors in the market, key players include:
Creative Bioarray
Agilent Technologies, Inc.
Hemogenix Inc.
Merck KGaA
Molecular Devices, LLC.
Miltenyi Biotec
FUJIFILM Cellular Dynamics
Enzo Life Sciences, Inc.
Axol Bioscience Ltd.
emka TECHNOLOGIES
Eurofins Discovery
Stemina Biomarker Discovery, Inc.
Evotec
Outline of Major Chapters:
Chapter 1: Introduces the definition of Multiparametric In-vitro Cardiotoxicity Testing, market overview.
Chapter 2: Global Multiparametric In-vitro Cardiotoxicity Testing market size in revenue.
Chapter 3: Detailed analysis of Multiparametric In-vitro Cardiotoxicity Testing company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type of assay, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Multiparametric In-vitro Cardiotoxicity Testing in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Multiparametric In-vitro Cardiotoxicity Testing Market, Global Outlook and Forecast 2024-2030 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2023 |
| Forecast Year |
2031 |
| Number of Pages |
68 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Multiparametric In-vitro Cardiotoxicity Testing Market Definition
1.2 Market Segments
1.2.1 Market by Type of Assay
1.2.2 Market by Application
1.3 Global Multiparametric In-vitro Cardiotoxicity Testing Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Multiparametric In-vitro Cardiotoxicity Testing Overall Market Size
2.1 Global Multiparametric In-vitro Cardiotoxicity Testing Market Size: 2023 VS 2030
2.2 Global Multiparametric In-vitro Cardiotoxicity Testing Market Size, Prospects & Forecasts: 2020-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Multiparametric In-vitro Cardiotoxicity Testing Players in Global Market
3.2 Top Global Multiparametric In-vitro Cardiotoxicity Testing Companies Ranked by Revenue
3.3 Global Multiparametric In-vitro Cardiotoxicity Testing Revenue by Companies
3.4 Top 3 and Top 5 Multiparametric In-vitro Cardiotoxicity Testing Companies in Global Market, by Revenue in 2023
3.5 Global Companies Multiparametric In-vitro Cardiotoxicity Testing Product Type
3.6 Tier 1, Tier 2 and Tier 3 Multiparametric In-vitro Cardiotoxicity Testing Players in Global Market
3.6.1 List of Global Tier 1 Multiparametric In-vitro Cardiotoxicity Testing Companies
3.6.2 List of Global Tier 2 and Tier 3 Multiparametric In-vitro Cardiotoxicity Testing Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type of Assay - Global Multiparametric In-vitro Cardiotoxicity Testing Market Size Markets, 2023 & 2030
4.1.2 Calcium Transient Assay
4.1.3 Cardiac Marker Detection
4.1.4 hERG Assay
4.1.5 Multi-ion Channel Assay
4.1.6 Others
4.2 By Type of Assay - Global Multiparametric In-vitro Cardiotoxicity Testing Revenue & Forecasts
4.2.1 By Type of Assay - Global Multiparametric In-vitro Cardiotoxicity Testing Revenue, 2020-2024
4.2.2 By Type of Assay - Global Multiparametric In-vitro Cardiotoxicity Testing Revenue, 2025-2030
4.2.3 By Type of Assay - Global Multiparametric In-vitro Cardiotoxicity Testing Revenue Market Share, 2020-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Multiparametric In-vitro Cardiotoxicity Testing Market Size, 2023 & 2030
5.1.2 Contract Research Organizations (CROs)
5.1.3 Pharmaceutical and Biotech Companies
5.1.4 Others
5.2 By Application - Global Multiparametric In-vitro Cardiotoxicity Testing Revenue & Forecasts
5.2.1 By Application - Global Multiparametric In-vitro Cardiotoxicity Testing Revenue, 2020-2024
5.2.2 By Application - Global Multiparametric In-vitro Cardiotoxicity Testing Revenue, 2025-2030
5.2.3 By Application - Global Multiparametric In-vitro Cardiotoxicity Testing Revenue Market Share, 2020-2030
6 Sights by Region
6.1 By Region - Global Multiparametric In-vitro Cardiotoxicity Testing Market Size, 2023 & 2030
6.2 By Region - Global Multiparametric In-vitro Cardiotoxicity Testing Revenue & Forecasts
6.2.1 By Region - Global Multiparametric In-vitro Cardiotoxicity Testing Revenue, 2020-2024
6.2.2 By Region - Global Multiparametric In-vitro Cardiotoxicity Testing Revenue, 2025-2030
6.2.3 By Region - Global Multiparametric In-vitro Cardiotoxicity Testing Revenue Market Share, 2020-2030
6.3 North America
6.3.1 By Country - North America Multiparametric In-vitro Cardiotoxicity Testing Revenue, 2020-2030
6.3.2 US Multiparametric In-vitro Cardiotoxicity Testing Market Size, 2020-2030
6.3.3 Canada Multiparametric In-vitro Cardiotoxicity Testing Market Size, 2020-2030
6.3.4 Mexico Multiparametric In-vitro Cardiotoxicity Testing Market Size, 2020-2030
6.4 Europe
6.4.1 By Country - Europe Multiparametric In-vitro Cardiotoxicity Testing Revenue, 2020-2030
6.4.2 Germany Multiparametric In-vitro Cardiotoxicity Testing Market Size, 2020-2030
6.4.3 France Multiparametric In-vitro Cardiotoxicity Testing Market Size, 2020-2030
6.4.4 U.K. Multiparametric In-vitro Cardiotoxicity Testing Market Size, 2020-2030
6.4.5 Italy Multiparametric In-vitro Cardiotoxicity Testing Market Size, 2020-2030
6.4.6 Russia Multiparametric In-vitro Cardiotoxicity Testing Market Size, 2020-2030
6.4.7 Nordic Countries Multiparametric In-vitro Cardiotoxicity Testing Market Size, 2020-2030
6.4.8 Benelux Multiparametric In-vitro Cardiotoxicity Testing Market Size, 2020-2030
6.5 Asia
6.5.1 By Region - Asia Multiparametric In-vitro Cardiotoxicity Testing Revenue, 2020-2030
6.5.2 China Multiparametric In-vitro Cardiotoxicity Testing Market Size, 2020-2030
6.5.3 Japan Multiparametric In-vitro Cardiotoxicity Testing Market Size, 2020-2030
6.5.4 South Korea Multiparametric In-vitro Cardiotoxicity Testing Market Size, 2020-2030
6.5.5 Southeast Asia Multiparametric In-vitro Cardiotoxicity Testing Market Size, 2020-2030
6.5.6 India Multiparametric In-vitro Cardiotoxicity Testing Market Size, 2020-2030
6.6 South America
6.6.1 By Country - South America Multiparametric In-vitro Cardiotoxicity Testing Revenue, 2020-2030
6.6.2 Brazil Multiparametric In-vitro Cardiotoxicity Testing Market Size, 2020-2030
6.6.3 Argentina Multiparametric In-vitro Cardiotoxicity Testing Market Size, 2020-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Multiparametric In-vitro Cardiotoxicity Testing Revenue, 2020-2030
6.7.2 Turkey Multiparametric In-vitro Cardiotoxicity Testing Market Size, 2020-2030
6.7.3 Israel Multiparametric In-vitro Cardiotoxicity Testing Market Size, 2020-2030
6.7.4 Saudi Arabia Multiparametric In-vitro Cardiotoxicity Testing Market Size, 2020-2030
6.7.5 UAE Multiparametric In-vitro Cardiotoxicity Testing Market Size, 2020-2030
7 Multiparametric In-vitro Cardiotoxicity Testing Companies Profiles
7.1 Creative Bioarray
7.1.1 Creative Bioarray Company Summary
7.1.2 Creative Bioarray Business Overview
7.1.3 Creative Bioarray Multiparametric In-vitro Cardiotoxicity Testing Major Product Offerings
7.1.4 Creative Bioarray Multiparametric In-vitro Cardiotoxicity Testing Revenue in Global Market (2020-2024)
7.1.5 Creative Bioarray Key News & Latest Developments
7.2 Agilent Technologies, Inc.
7.2.1 Agilent Technologies, Inc. Company Summary
7.2.2 Agilent Technologies, Inc. Business Overview
7.2.3 Agilent Technologies, Inc. Multiparametric In-vitro Cardiotoxicity Testing Major Product Offerings
7.2.4 Agilent Technologies, Inc. Multiparametric In-vitro Cardiotoxicity Testing Revenue in Global Market (2020-2024)
7.2.5 Agilent Technologies, Inc. Key News & Latest Developments
7.3 Hemogenix Inc.
7.3.1 Hemogenix Inc. Company Summary
7.3.2 Hemogenix Inc. Business Overview
7.3.3 Hemogenix Inc. Multiparametric In-vitro Cardiotoxicity Testing Major Product Offerings
7.3.4 Hemogenix Inc. Multiparametric In-vitro Cardiotoxicity Testing Revenue in Global Market (2020-2024)
7.3.5 Hemogenix Inc. Key News & Latest Developments
7.4 Merck KGaA
7.4.1 Merck KGaA Company Summary
7.4.2 Merck KGaA Business Overview
7.4.3 Merck KGaA Multiparametric In-vitro Cardiotoxicity Testing Major Product Offerings
7.4.4 Merck KGaA Multiparametric In-vitro Cardiotoxicity Testing Revenue in Global Market (2020-2024)
7.4.5 Merck KGaA Key News & Latest Developments
7.5 Molecular Devices, LLC.
7.5.1 Molecular Devices, LLC. Company Summary
7.5.2 Molecular Devices, LLC. Business Overview
7.5.3 Molecular Devices, LLC. Multiparametric In-vitro Cardiotoxicity Testing Major Product Offerings
7.5.4 Molecular Devices, LLC. Multiparametric In-vitro Cardiotoxicity Testing Revenue in Global Market (2020-2024)
7.5.5 Molecular Devices, LLC. Key News & Latest Developments
7.6 Miltenyi Biotec
7.6.1 Miltenyi Biotec Company Summary
7.6.2 Miltenyi Biotec Business Overview
7.6.3 Miltenyi Biotec Multiparametric In-vitro Cardiotoxicity Testing Major Product Offerings
7.6.4 Miltenyi Biotec Multiparametric In-vitro Cardiotoxicity Testing Revenue in Global Market (2020-2024)
7.6.5 Miltenyi Biotec Key News & Latest Developments
7.7 FUJIFILM Cellular Dynamics
7.7.1 FUJIFILM Cellular Dynamics Company Summary
7.7.2 FUJIFILM Cellular Dynamics Business Overview
7.7.3 FUJIFILM Cellular Dynamics Multiparametric In-vitro Cardiotoxicity Testing Major Product Offerings
7.7.4 FUJIFILM Cellular Dynamics Multiparametric In-vitro Cardiotoxicity Testing Revenue in Global Market (2020-2024)
7.7.5 FUJIFILM Cellular Dynamics Key News & Latest Developments
7.8 Enzo Life Sciences, Inc.
7.8.1 Enzo Life Sciences, Inc. Company Summary
7.8.2 Enzo Life Sciences, Inc. Business Overview
7.8.3 Enzo Life Sciences, Inc. Multiparametric In-vitro Cardiotoxicity Testing Major Product Offerings
7.8.4 Enzo Life Sciences, Inc. Multiparametric In-vitro Cardiotoxicity Testing Revenue in Global Market (2020-2024)
7.8.5 Enzo Life Sciences, Inc. Key News & Latest Developments
7.9 Axol Bioscience Ltd.
7.9.1 Axol Bioscience Ltd. Company Summary
7.9.2 Axol Bioscience Ltd. Business Overview
7.9.3 Axol Bioscience Ltd. Multiparametric In-vitro Cardiotoxicity Testing Major Product Offerings
7.9.4 Axol Bioscience Ltd. Multiparametric In-vitro Cardiotoxicity Testing Revenue in Global Market (2020-2024)
7.9.5 Axol Bioscience Ltd. Key News & Latest Developments
7.10 emka TECHNOLOGIES
7.10.1 emka TECHNOLOGIES Company Summary
7.10.2 emka TECHNOLOGIES Business Overview
7.10.3 emka TECHNOLOGIES Multiparametric In-vitro Cardiotoxicity Testing Major Product Offerings
7.10.4 emka TECHNOLOGIES Multiparametric In-vitro Cardiotoxicity Testing Revenue in Global Market (2020-2024)
7.10.5 emka TECHNOLOGIES Key News & Latest Developments
7.11 Eurofins Discovery
7.11.1 Eurofins Discovery Company Summary
7.11.2 Eurofins Discovery Business Overview
7.11.3 Eurofins Discovery Multiparametric In-vitro Cardiotoxicity Testing Major Product Offerings
7.11.4 Eurofins Discovery Multiparametric In-vitro Cardiotoxicity Testing Revenue in Global Market (2020-2024)
7.11.5 Eurofins Discovery Key News & Latest Developments
7.12 Stemina Biomarker Discovery, Inc.
7.12.1 Stemina Biomarker Discovery, Inc. Company Summary
7.12.2 Stemina Biomarker Discovery, Inc. Business Overview
7.12.3 Stemina Biomarker Discovery, Inc. Multiparametric In-vitro Cardiotoxicity Testing Major Product Offerings
7.12.4 Stemina Biomarker Discovery, Inc. Multiparametric In-vitro Cardiotoxicity Testing Revenue in Global Market (2020-2024)
7.12.5 Stemina Biomarker Discovery, Inc. Key News & Latest Developments
7.13 Evotec
7.13.1 Evotec Company Summary
7.13.2 Evotec Business Overview
7.13.3 Evotec Multiparametric In-vitro Cardiotoxicity Testing Major Product Offerings
7.13.4 Evotec Multiparametric In-vitro Cardiotoxicity Testing Revenue in Global Market (2020-2024)
7.13.5 Evotec Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Multiparametric In-vitro Cardiotoxicity Testing Market Opportunities & Trends in Global Market
Table 2. Multiparametric In-vitro Cardiotoxicity Testing Market Drivers in Global Market
Table 3. Multiparametric In-vitro Cardiotoxicity Testing Market Restraints in Global Market
Table 4. Key Players of Multiparametric In-vitro Cardiotoxicity Testing in Global Market
Table 5. Top Multiparametric In-vitro Cardiotoxicity Testing Players in Global Market, Ranking by Revenue (2023)
Table 6. Global Multiparametric In-vitro Cardiotoxicity Testing Revenue by Companies, (US$, Mn), 2020-2024
Table 7. Global Multiparametric In-vitro Cardiotoxicity Testing Revenue Share by Companies, 2020-2024
Table 8. Global Companies Multiparametric In-vitro Cardiotoxicity Testing Product Type
Table 9. List of Global Tier 1 Multiparametric In-vitro Cardiotoxicity Testing Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Multiparametric In-vitro Cardiotoxicity Testing Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 11. By Type of Assay ? Global Multiparametric In-vitro Cardiotoxicity Testing Revenue, (US$, Mn), 2023 & 2030
Table 12. By Type of Assay - Multiparametric In-vitro Cardiotoxicity Testing Revenue in Global (US$, Mn), 2020-2024
Table 13. By Type of Assay - Multiparametric In-vitro Cardiotoxicity Testing Revenue in Global (US$, Mn), 2025-2030
Table 14. By Application ? Global Multiparametric In-vitro Cardiotoxicity Testing Revenue, (US$, Mn), 2023 & 2030
Table 15. By Application - Multiparametric In-vitro Cardiotoxicity Testing Revenue in Global (US$, Mn), 2020-2024
Table 16. By Application - Multiparametric In-vitro Cardiotoxicity Testing Revenue in Global (US$, Mn), 2025-2030
Table 17. By Region ? Global Multiparametric In-vitro Cardiotoxicity Testing Revenue, (US$, Mn), 2023 & 2030
Table 18. By Region - Global Multiparametric In-vitro Cardiotoxicity Testing Revenue (US$, Mn), 2020-2024
Table 19. By Region - Global Multiparametric In-vitro Cardiotoxicity Testing Revenue (US$, Mn), 2025-2030
Table 20. By Country - North America Multiparametric In-vitro Cardiotoxicity Testing Revenue, (US$, Mn), 2020-2024
Table 21. By Country - North America Multiparametric In-vitro Cardiotoxicity Testing Revenue, (US$, Mn), 2025-2030
Table 22. By Country - Europe Multiparametric In-vitro Cardiotoxicity Testing Revenue, (US$, Mn), 2020-2024
Table 23. By Country - Europe Multiparametric In-vitro Cardiotoxicity Testing Revenue, (US$, Mn), 2025-2030
Table 24. By Region - Asia Multiparametric In-vitro Cardiotoxicity Testing Revenue, (US$, Mn), 2020-2024
Table 25. By Region - Asia Multiparametric In-vitro Cardiotoxicity Testing Revenue, (US$, Mn), 2025-2030
Table 26. By Country - South America Multiparametric In-vitro Cardiotoxicity Testing Revenue, (US$, Mn), 2020-2024
Table 27. By Country - South America Multiparametric In-vitro Cardiotoxicity Testing Revenue, (US$, Mn), 2025-2030
Table 28. By Country - Middle East & Africa Multiparametric In-vitro Cardiotoxicity Testing Revenue, (US$, Mn), 2020-2024
Table 29. By Country - Middle East & Africa Multiparametric In-vitro Cardiotoxicity Testing Revenue, (US$, Mn), 2025-2030
Table 30. Creative Bioarray Company Summary
Table 31. Creative Bioarray Multiparametric In-vitro Cardiotoxicity Testing Product Offerings
Table 32. Creative Bioarray Multiparametric In-vitro Cardiotoxicity Testing Revenue (US$, Mn) & (2020-2024)
Table 33. Creative Bioarray Key News & Latest Developments
Table 34. Agilent Technologies, Inc. Company Summary
Table 35. Agilent Technologies, Inc. Multiparametric In-vitro Cardiotoxicity Testing Product Offerings
Table 36. Agilent Technologies, Inc. Multiparametric In-vitro Cardiotoxicity Testing Revenue (US$, Mn) & (2020-2024)
Table 37. Agilent Technologies, Inc. Key News & Latest Developments
Table 38. Hemogenix Inc. Company Summary
Table 39. Hemogenix Inc. Multiparametric In-vitro Cardiotoxicity Testing Product Offerings
Table 40. Hemogenix Inc. Multiparametric In-vitro Cardiotoxicity Testing Revenue (US$, Mn) & (2020-2024)
Table 41. Hemogenix Inc. Key News & Latest Developments
Table 42. Merck KGaA Company Summary
Table 43. Merck KGaA Multiparametric In-vitro Cardiotoxicity Testing Product Offerings
Table 44. Merck KGaA Multiparametric In-vitro Cardiotoxicity Testing Revenue (US$, Mn) & (2020-2024)
Table 45. Merck KGaA Key News & Latest Developments
Table 46. Molecular Devices, LLC. Company Summary
Table 47. Molecular Devices, LLC. Multiparametric In-vitro Cardiotoxicity Testing Product Offerings
Table 48. Molecular Devices, LLC. Multiparametric In-vitro Cardiotoxicity Testing Revenue (US$, Mn) & (2020-2024)
Table 49. Molecular Devices, LLC. Key News & Latest Developments
Table 50. Miltenyi Biotec Company Summary
Table 51. Miltenyi Biotec Multiparametric In-vitro Cardiotoxicity Testing Product Offerings
Table 52. Miltenyi Biotec Multiparametric In-vitro Cardiotoxicity Testing Revenue (US$, Mn) & (2020-2024)
Table 53. Miltenyi Biotec Key News & Latest Developments
Table 54. FUJIFILM Cellular Dynamics Company Summary
Table 55. FUJIFILM Cellular Dynamics Multiparametric In-vitro Cardiotoxicity Testing Product Offerings
Table 56. FUJIFILM Cellular Dynamics Multiparametric In-vitro Cardiotoxicity Testing Revenue (US$, Mn) & (2020-2024)
Table 57. FUJIFILM Cellular Dynamics Key News & Latest Developments
Table 58. Enzo Life Sciences, Inc. Company Summary
Table 59. Enzo Life Sciences, Inc. Multiparametric In-vitro Cardiotoxicity Testing Product Offerings
Table 60. Enzo Life Sciences, Inc. Multiparametric In-vitro Cardiotoxicity Testing Revenue (US$, Mn) & (2020-2024)
Table 61. Enzo Life Sciences, Inc. Key News & Latest Developments
Table 62. Axol Bioscience Ltd. Company Summary
Table 63. Axol Bioscience Ltd. Multiparametric In-vitro Cardiotoxicity Testing Product Offerings
Table 64. Axol Bioscience Ltd. Multiparametric In-vitro Cardiotoxicity Testing Revenue (US$, Mn) & (2020-2024)
Table 65. Axol Bioscience Ltd. Key News & Latest Developments
Table 66. emka TECHNOLOGIES Company Summary
Table 67. emka TECHNOLOGIES Multiparametric In-vitro Cardiotoxicity Testing Product Offerings
Table 68. emka TECHNOLOGIES Multiparametric In-vitro Cardiotoxicity Testing Revenue (US$, Mn) & (2020-2024)
Table 69. emka TECHNOLOGIES Key News & Latest Developments
Table 70. Eurofins Discovery Company Summary
Table 71. Eurofins Discovery Multiparametric In-vitro Cardiotoxicity Testing Product Offerings
Table 72. Eurofins Discovery Multiparametric In-vitro Cardiotoxicity Testing Revenue (US$, Mn) & (2020-2024)
Table 73. Eurofins Discovery Key News & Latest Developments
Table 74. Stemina Biomarker Discovery, Inc. Company Summary
Table 75. Stemina Biomarker Discovery, Inc. Multiparametric In-vitro Cardiotoxicity Testing Product Offerings
Table 76. Stemina Biomarker Discovery, Inc. Multiparametric In-vitro Cardiotoxicity Testing Revenue (US$, Mn) & (2020-2024)
Table 77. Stemina Biomarker Discovery, Inc. Key News & Latest Developments
Table 78. Evotec Company Summary
Table 79. Evotec Multiparametric In-vitro Cardiotoxicity Testing Product Offerings
Table 80. Evotec Multiparametric In-vitro Cardiotoxicity Testing Revenue (US$, Mn) & (2020-2024)
Table 81. Evotec Key News & Latest Developments
List of Figures
Figure 1. Multiparametric In-vitro Cardiotoxicity Testing Segment by Type of Assay in 2023
Figure 2. Multiparametric In-vitro Cardiotoxicity Testing Segment by Application in 2023
Figure 3. Global Multiparametric In-vitro Cardiotoxicity Testing Market Overview: 2023
Figure 4. Key Caveats
Figure 5. Global Multiparametric In-vitro Cardiotoxicity Testing Market Size: 2023 VS 2030 (US$, Mn)
Figure 6. Global Multiparametric In-vitro Cardiotoxicity Testing Revenue, 2020-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Multiparametric In-vitro Cardiotoxicity Testing Revenue in 2023
Figure 8. By Type of Assay - Global Multiparametric In-vitro Cardiotoxicity Testing Revenue Market Share, 2020-2030
Figure 9. By Application - Global Multiparametric In-vitro Cardiotoxicity Testing Revenue Market Share, 2020-2030
Figure 10. By Type of Assay - Global Multiparametric In-vitro Cardiotoxicity Testing Revenue, (US$, Mn), 2023 & 2030
Figure 11. By Type of Assay - Global Multiparametric In-vitro Cardiotoxicity Testing Revenue Market Share, 2020-2030
Figure 12. By Application - Global Multiparametric In-vitro Cardiotoxicity Testing Revenue, (US$, Mn), 2023 & 2030
Figure 13. By Application - Global Multiparametric In-vitro Cardiotoxicity Testing Revenue Market Share, 2020-2030
Figure 14. By Region - Global Multiparametric In-vitro Cardiotoxicity Testing Revenue Market Share, 2020-2030
Figure 15. By Country - North America Multiparametric In-vitro Cardiotoxicity Testing Revenue Market Share, 2020-2030
Figure 16. US Multiparametric In-vitro Cardiotoxicity Testing Revenue, (US$, Mn), 2020-2030
Figure 17. Canada Multiparametric In-vitro Cardiotoxicity Testing Revenue, (US$, Mn), 2020-2030
Figure 18. Mexico Multiparametric In-vitro Cardiotoxicity Testing Revenue, (US$, Mn), 2020-2030
Figure 19. By Country - Europe Multiparametric In-vitro Cardiotoxicity Testing Revenue Market Share, 2020-2030
Figure 20. Germany Multiparametric In-vitro Cardiotoxicity Testing Revenue, (US$, Mn), 2020-2030
Figure 21. France Multiparametric In-vitro Cardiotoxicity Testing Revenue, (US$, Mn), 2020-2030
Figure 22. U.K. Multiparametric In-vitro Cardiotoxicity Testing Revenue, (US$, Mn), 2020-2030
Figure 23. Italy Multiparametric In-vitro Cardiotoxicity Testing Revenue, (US$, Mn), 2020-2030
Figure 24. Russia Multiparametric In-vitro Cardiotoxicity Testing Revenue, (US$, Mn), 2020-2030
Figure 25. Nordic Countries Multiparametric In-vitro Cardiotoxicity Testing Revenue, (US$, Mn), 2020-2030
Figure 26. Benelux Multiparametric In-vitro Cardiotoxicity Testing Revenue, (US$, Mn), 2020-2030
Figure 27. By Region - Asia Multiparametric In-vitro Cardiotoxicity Testing Revenue Market Share, 2020-2030
Figure 28. China Multiparametric In-vitro Cardiotoxicity Testing Revenue, (US$, Mn), 2020-2030
Figure 29. Japan Multiparametric In-vitro Cardiotoxicity Testing Revenue, (US$, Mn), 2020-2030
Figure 30. South Korea Multiparametric In-vitro Cardiotoxicity Testing Revenue, (US$, Mn), 2020-2030
Figure 31. Southeast Asia Multiparametric In-vitro Cardiotoxicity Testing Revenue, (US$, Mn), 2020-2030
Figure 32. India Multiparametric In-vitro Cardiotoxicity Testing Revenue, (US$, Mn), 2020-2030
Figure 33. By Country - South America Multiparametric In-vitro Cardiotoxicity Testing Revenue Market Share, 2020-2030
Figure 34. Brazil Multiparametric In-vitro Cardiotoxicity Testing Revenue, (US$, Mn), 2020-2030
Figure 35. Argentina Multiparametric In-vitro Cardiotoxicity Testing Revenue, (US$, Mn), 2020-2030
Figure 36. By Country - Middle East & Africa Multiparametric In-vitro Cardiotoxicity Testing Revenue Market Share, 2020-2030
Figure 37. Turkey Multiparametric In-vitro Cardiotoxicity Testing Revenue, (US$, Mn), 2020-2030
Figure 38. Israel Multiparametric In-vitro Cardiotoxicity Testing Revenue, (US$, Mn), 2020-2030
Figure 39. Saudi Arabia Multiparametric In-vitro Cardiotoxicity Testing Revenue, (US$, Mn), 2020-2030
Figure 40. UAE Multiparametric In-vitro Cardiotoxicity Testing Revenue, (US$, Mn), 2020-2030
Figure 41. Creative Bioarray Multiparametric In-vitro Cardiotoxicity Testing Revenue Year Over Year Growth (US$, Mn) & (2020-2024)
Figure 42. Agilent Technologies, Inc. Multiparametric In-vitro Cardiotoxicity Testing Revenue Year Over Year Growth (US$, Mn) & (2020-2024)
Figure 43. Hemogenix Inc. Multiparametric In-vitro Cardiotoxicity Testing Revenue Year Over Year Growth (US$, Mn) & (2020-2024)
Figure 44. Merck KGaA Multiparametric In-vitro Cardiotoxicity Testing Revenue Year Over Year Growth (US$, Mn) & (2020-2024)
Figure 45. Molecular Devices, LLC. Multiparametric In-vitro Cardiotoxicity Testing Revenue Year Over Year Growth (US$, Mn) & (2020-2024)
Figure 46. Miltenyi Biotec Multiparametric In-vitro Cardiotoxicity Testing Revenue Year Over Year Growth (US$, Mn) & (2020-2024)
Figure 47. FUJIFILM Cellular Dynamics Multiparametric In-vitro Cardiotoxicity Testing Revenue Year Over Year Growth (US$, Mn) & (2020-2024)
Figure 48. Enzo Life Sciences, Inc. Multiparametric In-vitro Cardiotoxicity Testing Revenue Year Over Year Growth (US$, Mn) & (2020-2024)
Figure 49. Axol Bioscience Ltd. Multiparametric In-vitro Cardiotoxicity Testing Revenue Year Over Year Growth (US$, Mn) & (2020-2024)
Figure 50. emka TECHNOLOGIES Multiparametric In-vitro Cardiotoxicity Testing Revenue Year Over Year Growth (US$, Mn) & (2020-2024)
Figure 51. Eurofins Discovery Multiparametric In-vitro Cardiotoxicity Testing Revenue Year Over Year Growth (US$, Mn) & (2020-2024)
Figure 52. Stemina Biomarker Discovery, Inc. Multiparametric In-vitro Cardiotoxicity Testing Revenue Year Over Year Growth (US$, Mn) & (2020-2024)
Figure 53. Evotec Multiparametric In-vitro Cardiotoxicity Testing Revenue Year Over Year Growth (US$, Mn) & (2020-2024)
